ArticleMedicine2026
Outcomes and predictors of atrial fibrillation in cardiac amyloidosis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis (CA) frequently coexists with atrial fibrillation (AF), but the extent and impact of this relationship remain unclear. This study investigates the prevalence of AF in CA, compares clinical characteristics between amyloid light-chain (AL)-CA and amyloid transthyretin (ATTR)-CA, and assesses the implications for treatment strategies. We conducted a retrospective analysis of 108 patients with confirmed CA, categorizing them into 2 groups: 51 with AF and 57 with sinus rhythm (SR). We compared demographic, clinical, and echocardiographic data, as well as treatment modalities and outcomes between AL-CA and ATTR-CA subgroups. AF was present in 47% of the cohort, with a notably higher prevalence in wild-type ATTR-CA (80%) compared to AL-CA (33%). Patients with AF were older (73.8 ± 8.5 years) than those with SR (67.7 ± 10.6 years, P < .001) and had more severe heart failure symptoms, comorbidities, and echocardiographic abnormalities, including reduced left ventricular ejection fraction (LVEF; 47% vs 53%, P = .003) and higher pulmonary artery pressures (41 ± 11 mm Hg vs 35 ± 17 mm Hg, P = .02). Logistic regression identified BMI (OR 1.2, 95% CI: 1.05-1.57, P = .02) and eGFR (OR 0.91, 95% CI: 0.92-0.99, P = .04) as independent predictors of AF. CHA2DS2-VASc scores were higher in ATTR-CA patients (4.5 ± 1.2) compared to AL-CA (2.4 ± 1.1, P < .001). Despite a high rate of anticoagulation (78%), ischemic stroke or TIA incidence was low at 6% over 12 months. AF is highly prevalent in CA, particularly in ATTR-CA, and is associated with more severe clinical manifestations. The findings highlight the necessity for systematic AF screening and tailored management strategies in CA patients. Prospective, randomized studies are essential to establish optimal AF treatment protocols in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.